adenosine has been researched along with Thrombosis in 120 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (8.33) | 18.7374 |
1990's | 11 (9.17) | 18.2507 |
2000's | 12 (10.00) | 29.6817 |
2010's | 81 (67.50) | 24.3611 |
2020's | 6 (5.00) | 2.80 |
Authors | Studies |
---|---|
Han, K; Huang, X; Ma, M; Sun, T; Yang, S; Zhao, Z; Zhou, Y | 1 |
Cheung, SS; Hellsten, Y; Lundberg Slingsby, MH; Nørregaard, LB; Wickham, KA | 1 |
Cheng, XD; Li, YJ; Wang, JH; Wang, L; Yang, B; Yang, X; Yu, NW; Zhang, J; Zhang, Q; Zhang, X | 1 |
Arthur, JM; Arulprakash, N; Corken, A; Dai, J; Davis, O; Hedayati, SS; Jain, N; Mehta, JL; Phadnis, MA; Rahmatallah, Y; Smyth, S; Ware, J | 1 |
Rozalski, M; Wolska, N | 1 |
Altun, S; Çetinbaş, A; Okur, Mİ; Özercan, İ; Öztan, M; Yıldız Altun, A | 1 |
Altié, A; Brouilly, N; Carminita, E; Crescence, L; Dubois, C; Panicot-Dubois, L | 1 |
Cui, JG; Huang, XH; Liu, G; Lu, J; Wu, X; Zhao, XY; Zheng, XX | 1 |
Budaj, A; Ramotowski, B; Żuk, A | 1 |
Anuwatworn, A; Kumar, V; Petrasko, M; Stys, A; Yee, J | 1 |
Dobesh, PP; Patel, M | 1 |
Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY | 1 |
Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H | 1 |
Asseburg, C; Giannitsis, E; Katus, H; Theidel, U | 1 |
Bode, C; Boeynaems, JM; Duerschmied, D; Guenther, F; Hein, L; Herr, N; Idzko, M; Mauler, M; Robaye, B; Roming, F; Von Zur Muhlen, C; Witsch, T | 1 |
Becker, RC; Cannon, CP; Harrington, RA; James, SK; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 2 |
Abtahian, F; Hu, S; Jang, IK; Jia, H; Kato, K; McNulty, I; Tian, J; Vergallo, R; Yonetsu, T | 1 |
Biondi-Zoccai, G; Dinicolantonio, JJ | 1 |
Cameron, AM; Cengiz-Seval, G; Girotra, M; Gulsen, MT; Gurakar, A; Price, J; Segev, DL; Singh, VK | 1 |
DiNicolantonio, JJ; Serebruany, VL | 1 |
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
Casassus, F; Fiore, M; Horovitz, A; Leroux, L; Pons, AC | 1 |
Hartmark-Hill, JR; Tsang, K | 1 |
Bäckstrom, J; Bhal, V; Caughran, AT; Enerbäck, M; Houng, AK; Houser, KH; Jennings, LK; Lands, LT; Reed, GL; Speich, HE | 1 |
Angiolillo, DJ; Capodanno, D | 1 |
Bouatou, Y; Gabrielli, A; Saudan, P | 1 |
Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E | 1 |
Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Lambert, M; Morange, P; Pankert, M; Quilici, J; Verdier, V | 1 |
Ge, J; Qian, J; Wang, Q; Wu, H; Zhou, J | 1 |
Dobesh, PP; Oestreich, JH | 1 |
Bacchini, S; Bongo, AS; Brunelleschi, S; Cavallino, C; Lupi, A; Rametta, F; Rognoni, A; Rosso, R; Secco, GG; Veia, A | 1 |
Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
Alarcón, M; Caballero, J; Fuentes, E; Mezzano, D; Palomo, I; Pereira, J | 1 |
Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H | 1 |
Cho, JH; Ihm, CG; Jeong, KH; Kim, JB; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS | 1 |
Dhillon, S | 1 |
Keaney, JF | 1 |
Kanorskiĭ, SG | 1 |
Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH | 1 |
Fuentes, E; Palomo, I | 1 |
Al-Kindi, SG; Benatti, RD; Deo, S; ElAmm, C; Ginwalla, M; Medalion, B; Oliveira, GH; Osman, MN; Park, SJ; Qattan, MY; Simon, DI | 1 |
Chua, T; Gruntowicz, D; Johnson, SG; Morlock, RJ | 1 |
Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
Ajjan, RA; Dockrell, DH; Ecob, R; Faulkner, RE; Judge, HM; Khan, H; Outteridge, SN; Phoenix, F; Sabroe, I; Sangha, GK; Storey, RF; Thomas, MR; West, LE | 1 |
Giusti, B; Grifoni, E; Marcucci, R | 1 |
Millar, CG; Noman, A; Parasuraman, SK; Teo, AI | 1 |
Abacı, A; Aygencel, G; Kara, İ; Okuyan, H; Türkoğlu, M; Yıldırım, F | 1 |
Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D | 1 |
Cattaneo, M; Cipriani, M; Femia, EA; Frigerio, M; Morici, N; Oliva, F; Perna, E | 1 |
Chepurko, E; Covarrubias, R; Cowan, PJ; Dwyer, KM; Gumina, RJ; Huttinger, R; Huttinger, ZM; Novitskaya, T; Reynolds, A; Robson, SC; Stanfill, K; Wheeler, DG | 1 |
Cattabiani, MA; Di Vito, L; Gatto, L; Limbruno, U; Marco, V; Micari, A; Pawlowski, T; Prati, F; Romagnoli, E; Trivisonno, A; Versaci, F | 1 |
Heath, RS; Hugentobler, KG; Rasparini, M; Sharif, H; Turner, NJ | 1 |
Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
Barillà, F; Borzi, M; Camici, P; Cas, LD; Di Biase, M; Filardi, PP; Indolfi, C; Mercuro, G; Montemurro, V; Padeletti, L; Pelliccia, F; Romeo, F; Vizza, CD | 1 |
Gurbel, PA; Kubica, J; Myat, A; Tantry, US | 1 |
Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M | 1 |
Akhmedov, A; Beer, JH; Bonetti, NR; Camici, GG; Gaul, DS; Glanzmann, M; Keller, S; Lüscher, TF; Matter, CM; Reiner, MF; Ruf, W; Savarese, G; Stivala, S; Yang, Z; Zhu, C | 1 |
Adeola, O; Chen, R; Fay, WP; Jeong, SS; Ji, Y; Strawn, TL | 1 |
Ariotti, S; Gargiulo, G; Valgimigli, M | 1 |
Chan, R; Kong, SL; Kwok, J; Lee, S; Shea, C; Siu, D; Tam, CC; Tang, WH; Wong, A; Yung, A | 1 |
Bonan, CD; Morsch, VM; Schetinger, MR; Wyse, AT | 1 |
Dai, J; Houard, X; Louedec, L; Michel, JB; Philippe, M | 1 |
Doggrell, SA | 1 |
Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H | 1 |
Angiolillo, DJ; Capodanno, D; Dharmashankar, K | 1 |
Kosior, D; Marczewski, MM; Postula, M | 1 |
Gurbel, PA; Kereiakes, DJ; Tantry, US | 1 |
Francis, SE; Jackman, LE; Judge, HM; Nylander, S; Patil, SB; Storey, RF | 1 |
Cayla, G; Collet, JP; Montalescot, G | 1 |
Gaglia, MA; Waksman, R | 1 |
Hamad, B; Huber, K; Kirkpatrick, P | 1 |
Storey, RF | 1 |
Chauhan, A; More, RS; Morgan, KP | 1 |
Ding, Z; Du, H; Fan, Z; Gross, PL; Hu, L; Kunapuli, SP; Ni, R; Wei, X; Ye, J; Yin, K; Zhang, S; Zhang, X; Zhang, Y | 1 |
De Mey, JG; Feijge, MA; Heemskerk, JW; Kuijpers, MJ; Megens, RT; Nikookhesal, E; oude Egbrink, MG; van Giezen, JJ | 1 |
Campbell, JA; Davis, EM; Knezevich, JT; Packard, KA | 1 |
Johnston-Cox, HA; Koupenova, M; Ravid, K | 1 |
Coulden, RA; Grundy, BJ; Khoo, JP; McCann, GP; Sonnex, EP; Steadman, CD | 1 |
Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T | 1 |
Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F | 1 |
Barn, K; Steinhubl, SR | 1 |
Giannitsis, E; Katus, HA | 1 |
Ding, Z; Du, H; Liu, G; Pan, C; Wei, X; Ye, J; Zhang, S; Zhang, Y | 1 |
Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L | 1 |
Dechant, LM | 1 |
Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A | 1 |
Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L | 1 |
Hashimoto, M; Jakubowski, J; Ogawa, T; Ohno, K; Sugidachi, A; Tomizawa, A | 1 |
BORN, GV; HONOUR, AJ; MITCHELL, JR | 1 |
PHILP, RB; WRIGHT, HP | 1 |
Campbell, DJ; Cowan, PJ; d'Apice, AJ; Dwyer, KM; Fisicaro, N; Gock, H; Kaczmarek, E; Murray-Segal, LJ; Mysore, TB; Nandurkar, HH; Robson, SC | 1 |
Heldman, AW; St John, M | 1 |
Humphries, RG; van Giezen, JJ | 1 |
Chen, JP | 1 |
Bailey, A; Barton, P; Birkinshaw, TN; Bonnert, RV; Brown, RC; Chapman, D; Dixon, J; Guile, SD; Humphries, RG; Hunt, SF; Ince, F; Ingall, AH; Kirk, IP; Leeson, PD; Leff, P; Lewis, RJ; Martin, BP; McGinnity, DF; Mortimore, MP; Paine, SW; Pairaudeau, G; Patel, A; Rigby, AJ; Riley, RJ; Springthorpe, B; Teobald, BJ; Tomlinson, W; Webborn, PJ; Willis, PA | 1 |
Angiolillo, DJ | 1 |
Ikeda, Y; Nagano, M; Nakashima, M; Takiguchi, Y | 1 |
Fisher, RA; Madden, R; Munda, R | 1 |
Benoit, G; Bensadoun, H; Blanchet, P; Charpentier, B; Douguet, D; Jaber, N; Jardin, A; Moukarzel, M | 1 |
Abecassis, MM; Douzdjian, V; Sharp, WJ | 1 |
Chiodini, S; Emre, S; Hytiroglou, P; Kishikawa, K; Menesses, P; Miller, CM; Mor, E; Schwartz, ME; Sheiner, PA | 1 |
Blumenstock, I; Büsing, M; Heimburger, N; Hopt, UT; Nader, A; Pfeffer, F; Schareck, W | 1 |
Abe, M; Babazono, T; Hoshino, T; Ishida, H; Koike, T; Nakamura, M; Sato, S; Shinkai, M; Teraoka, S; Tomonaga, O | 1 |
De Ville de Goyet, J; Gigi, J; Lerut, J; Martínez, JA; Otte, JB; Rahier, J; Reding, R; Rigamonti, W | 1 |
Nguyen, A | 1 |
Berndt, MC; Bobik, A; Jennings, G; Ramsay, D; Taylor, AJ | 1 |
Lewis, GP; Lieberman, GE; Peters, TJ | 1 |
Yasunaga, K | 1 |
Altomonte, F; Armani, U; Griffanti-Bartoli, F; Piana, A | 1 |
Born, GV; Galletti, PM; Richardson, PD | 1 |
Langnas, AN; Li, S; Marujo, W; Shaw, BW; Stratta, RJ; Wood, RP | 1 |
Baumann, FG; Crooke, G; Halff, GA; Harris, L; Teperman, LW; Weil, R | 1 |
Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Pirsch, JD; Sollinger, HW; Southard, JH | 1 |
Barbenel, JC; Forbes, CD; Lowe, GD; Madhok, R; Saniabadi, AR; Shaw, B; Spowart, K | 1 |
Banks, DC; Mitchell, JR | 1 |
Weiss, HJ | 1 |
Gowdey, CW; Philp, RB; Schacham, P | 1 |
31 review(s) available for adenosine and Thrombosis
Article | Year |
---|---|
Purinergic signaling: a potential therapeutic target for ischemic stroke.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Antigens, CD; Apyrase; Humans; Ischemic Stroke; Signal Transduction; Thrombosis | 2023 |
Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Blood Platelets; Cyclic AMP; Humans; Platelet Aggregation Inhibitors; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Thrombosis | 2019 |
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease.
Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease.
Topics: Adenosine; Atherosclerosis; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2017 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Drug Administration Schedule; Drug Costs; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; United States | 2013 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor | 2014 |
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Humans; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Treatment Outcome | 2014 |
Ticagrelor: a novel drug for an old problem.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Humans; Patents as Topic; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2014 |
Ticagrelor: a review of its use in adults with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aging; Combined Modality Therapy; Coronary Artery Bypass; Evidence-Based Medicine; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Thrombosis; Ticagrelor | 2015 |
Extracellular ATP metabolism on vascular endothelial cells: A pathway with pro-thrombotic and anti-thrombotic molecules.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; Blood Platelets; Endothelial Cells; Endothelium, Vascular; Humans; Platelet Activation; Thrombosis | 2015 |
On-treatment platelet reactivity: State of the art and perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Sex Factors; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.
Topics: Adenosine; Blood Platelets; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Treatment Outcome | 2017 |
NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; Atherosclerosis; Blood Coagulation; Blood Platelets; Cell Communication; Demyelinating Diseases; Epilepsy; Humans; Metabolism, Inborn Errors; Myocardial Infarction; Neoplasms; Platelet Activation; Platelet Aggregation; Seizures; Signal Transduction; Tamoxifen; Thrombosis | 2007 |
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor | 2010 |
Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.
Topics: Adenosine; Animals; Blood Platelets; Drugs, Investigational; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Treatment Outcome | 2010 |
Ticagrelor for the treatment of arterial thrombosis.
Topics: Adenosine; Arteries; Clinical Trials as Topic; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Treatment Outcome | 2010 |
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Coronary Artery Disease; Hemorrhage; Humans; Imines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticagrelor | 2012 |
A2 adenosine receptors and vascular pathologies.
Topics: Adenosine; Animals; Atherosclerosis; Blood Vessels; Humans; Inflammation; Receptors, Adenosine A2; Signal Transduction; Thrombosis; Vascular Diseases | 2012 |
[Platelet function: new drugs, new assays : possible impacts on operative medicine?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Predictive Value of Tests; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Animals; Arterial Occlusive Diseases; Clinical Trials as Topic; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Female; Fibrinolytic Agents; Humans; Injections, Intravenous; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Rabbits; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor | 2005 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2007 |
Prothrombin G20210A polymorphism and thrombophilia.
Topics: Adenosine; Africa; Asia; Asian People; Black People; Brain Ischemia; Brazil; Coronary Disease; Europe; Factor V; Genetic Testing; Guanosine; Homozygote; Humans; Point Mutation; Polymorphism, Genetic; Prevalence; Prothrombin; Risk Factors; Thrombophilia; Thrombosis; United States; White People | 2000 |
[Present status and prospects of platelet inhibitors].
Topics: Adenosine; Aspirin; Blood Platelets; Cyclic AMP; Cyclic GMP; Depression, Chemical; Drug Combinations; Drug Synergism; Humans; Phosphodiesterase Inhibitors; Platelet Aggregation; Prostaglandins E; Serotonin; Theophylline; Thrombosis | 1976 |
[The use of platelet aggregation inhibitor in nephrodialysis].
Topics: Adenosine; Blood Coagulation Disorders; Epoprostenol; Heparin; Humans; Platelet Aggregation; Prostaglandins; Prostaglandins E, Synthetic; Renal Dialysis; Thrombosis | 1979 |
15 trial(s) available for adenosine and Thrombosis
Article | Year |
---|---|
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease.
Topics: Adenosine; Clopidogrel; Female; Humans; Inflammation; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Topics: Adenosine; Aged; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Time Factors | 2018 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drugs, Generic; Follow-Up Studies; Germany; Humans; Markov Chains; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Quality-Adjusted Life Years; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Renal Dialysis; Single-Blind Method; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Sample Size; Thrombophilia; Thrombosis; Ticagrelor | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel; Cytokines; Endotoxins; England; Female; Fibrin Fibrinogen Degradation Products; Humans; Inflammation; Inflammation Mediators; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2015 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
Topics: Abciximab; Adenosine; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Thrombectomy; Thrombosis; Ticagrelor; Ticlopidine; Tomography, Optical Coherence | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Expression; Gene Frequency; Genotype; Genotyping Techniques; Humans; Male; Middle Aged; Mutation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Stents; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Prevention of early postoperative graft thrombosis in pancreatic transplantation.
Topics: Adenosine; Allopurinol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Glutathione; Humans; Hypertonic Solutions; Insulin; Kidney Failure, Chronic; Kidney Transplantation; Organ Preservation; Organ Preservation Solutions; Pancreas; Pancreas Transplantation; Postoperative Complications; Raffinose; Retrospective Studies; Thrombosis | 1993 |
74 other study(ies) available for adenosine and Thrombosis
Article | Year |
---|---|
Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.
Topics: Adenosine; Adenosine Diphosphate; Clopidogrel; Complement C1q; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Ticlopidine | 2022 |
High-Intensity Exercise Training Improves Basal Platelet Prostacyclin Sensitivity and Potentiates the Response to Dual Anti-Platelet Therapy in Postmenopausal Women.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Cyclooxygenase 1; Diphosphates; Dual Anti-Platelet Therapy; Epoprostenol; Estrogens; Exercise; Female; Humans; Nitric Oxide; Peptides; Platelet Aggregation Inhibitors; Postmenopause; Receptors, Epoprostenol; Receptors, Thromboxane; Thrombin; Thrombosis; Thromboxanes | 2022 |
The effect of ticagrelor on microarterial thrombosis in an experimental model.
Topics: Adenosine; Animals; Clopidogrel; Models, Theoretical; Platelet Aggregation Inhibitors; Rats; Thrombosis; Ticagrelor; Ticlopidine | 2021 |
DNAse-dependent, NET-independent pathway of thrombus formation in vivo.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Blood Platelets; Deoxyribonuclease I; Extracellular Traps; Fibrin; Humans; Hydrolysis; Lasers; Leukocyte Elastase; Mice, Inbred C57BL; Models, Biological; Neutrophil Activation; Neutrophils; Platelet Activation; Protein-Arginine Deiminase Type 4; Thrombosis | 2021 |
Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI.
Topics: Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Topics: Adenosine; Animals; Arachidonic Acid; Aspirin; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine; Vascular Resistance | 2013 |
Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition.
Topics: Adenosine; Animals; Anticoagulants; Chlorides; Contrast Media; Enoxaparin; Ferric Compounds; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbubbles; Microscopy; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Sulfur Hexafluoride; Thrombosis; Ticagrelor; Ultrasonography; Vena Cava, Inferior; Venous Thrombosis | 2013 |
Ticagrelor immediately prior to stenting is associated with smaller residual thrombus in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Care; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thrombosis; Ticagrelor | 2013 |
Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports.
Topics: Adenosine; Clopidogrel; Drug-Eluting Stents; Humans; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2013 |
HTK preservative solution is associated with increased biliary complications among patients receiving DCD liver transplants: a single center experience.
Topics: Adenosine; Adult; Allopurinol; Anastomosis, Surgical; Anastomotic Leak; Biliary Tract; Constriction, Pathologic; Female; Glucose; Glutathione; Hepatic Artery; Humans; Insulin; Liver Transplantation; Male; Mannitol; Middle Aged; Organ Preservation Solutions; Postoperative Complications; Potassium Chloride; Procaine; Raffinose; Reoperation; Retrospective Studies; Thrombosis; Tissue Donors | 2013 |
Letter by Serebruany and DiNicolantonio regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis | 2013 |
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis | 2013 |
First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor.
Topics: Adenosine; Drug Resistance; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis; Ticagrelor | 2014 |
Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Topics: Adenosine; Animals; Humans; Male; Mice; Mice, Inbred C57BL; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thrombosis; Ticagrelor; Time Factors | 2014 |
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Postoperative Care; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Retrospective Studies; Thiophenes; Thrombosis; Ticagrelor | 2014 |
First report of stent thrombosis after a switch therapy resulting from ticagrelor-related dyspnea.
Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Dyspnea; Humans; Male; Purinergic P2Y Receptor Antagonists; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Inhibition of platelet activation and thrombus formation by adenosine and inosine: studies on their relative contribution and molecular modeling.
Topics: Adenosine; Animals; Blood Coagulation; Blood Platelets; Collagen; Humans; Inosine; Male; Mice; Models, Biological; Platelet Adhesiveness; Thrombosis | 2014 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome; Warfarin | 2015 |
Balancing the risks and benefits of dual platelet inhibition.
Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
[ATLANTIC trial and feasibility of early administration of ticagrelor in myocardial infarction].
Topics: Adenosine; Coronary Circulation; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticagrelor; Time-to-Treatment; Treatment Outcome | 2014 |
Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Blood Platelets; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Predictive Value of Tests; Stents; Thrombosis; Ticagrelor | 2016 |
Platelet inhibition with ticagrelor for left ventricular assist device thrombosis.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Heart Failure; Heart-Assist Devices; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prosthesis Design; Thrombosis; Ticagrelor; Treatment Outcome; Ventricular Function, Left | 2015 |
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genetic Testing; Genotype; Humans; Managed Care Programs; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Patient Discharge; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Pneumonitis and pulmonary haemorrhage after acute myocardial infarction.
Topics: Adenosine; Angioplasty; Hemoptysis; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Pneumonia; Purinergic P2Y Receptor Antagonists; Radiography, Thoracic; Thrombosis; Ticagrelor | 2015 |
Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Fatal Outcome; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Thrombosis; Ticagrelor | 2017 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Ticagrelor for left ventricular assist device thrombosis: A new therapeutic option to be evaluated with caution.
Topics: Adenosine; Aged; Aspirin; Blood Coagulation; Cardiomyopathies; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Fibrinolytic Agents; Heart-Assist Devices; Humans; Male; Medication Therapy Management; Postoperative Complications; Risk Adjustment; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; Arterial Occlusive Diseases; Blood Coagulation; Bone Marrow Transplantation; Chlorides; Disease Models, Animal; Endothelial Cells; Ferric Compounds; Genetic Predisposition to Disease; HEK293 Cells; Humans; Hydrolysis; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Monocytes; Phenotype; Platelet Activation; Thrombosis; Time Factors; Transfection | 2016 |
Biocatalytic approaches to a key building block for the anti-thrombotic agent ticagrelor.
Topics: Adenosine; Amines; Biocatalysis; Chemistry Techniques, Synthetic; Hydrolysis; Thrombosis; Ticagrelor | 2016 |
Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
Topics: Adenosine; Aspirin; Cardiology; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Italy; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Societies, Medical; Thrombosis; Ticagrelor | 2017 |
In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
Topics: Adenosine; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Topics: Adenosine; Animals; Blood Coagulation; Blood Platelets; Carotid Artery Injuries; Cells, Cultured; Clopidogrel; Disease Models, Animal; Down-Regulation; Endothelial Cells; Equilibrative Nucleoside Transporter 1; Fibrinolytic Agents; Humans; Male; Mice, Inbred C57BL; Platelet Aggregation Inhibitors; Proteasome Endopeptidase Complex; Proteolysis; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thromboplastin; Thrombosis; Ticagrelor; Ticlopidine; Time Factors; Tumor Necrosis Factor-alpha | 2017 |
Recombinant soluble apyrase APT102 inhibits thrombosis and intimal hyperplasia in vein grafts without adversely affecting hemostasis or re-endothelialization.
Topics: Adenosine; Adenosine Triphosphatases; Animals; Apyrase; Blood Platelets; Blood Vessels; Carotid Arteries; Cell Movement; Cell Proliferation; Coronary Vessels; Endothelial Cells; Endothelium, Vascular; Hemostasis; Humans; Hyperplasia; Male; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Platelet Aggregation; Prothrombin Time; Recombinant Proteins; Solubility; Thrombosis; Tunica Intima | 2017 |
Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model.
Topics: Adenosine; Adenosine Diphosphate; Animals; Aorta; Aortic Aneurysm, Abdominal; Blood Platelets; Disease Models, Animal; Disease Progression; Elastic Tissue; Guinea Pigs; Inflammation; Male; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rats; Rats, Inbred Lew; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Time Factors; Transplantation, Heterologous | 2009 |
Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Molecular Structure; Platelet Aggregation Inhibitors; Structure-Activity Relationship; Thrombosis; Ticagrelor; Treatment Outcome | 2009 |
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection | 2009 |
Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Blood Platelets; Carotid Artery Injuries; Carotid Artery, Common; Carotid Stenosis; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Tunica Intima | 2010 |
Ticagrelor to prevent restenosis: new drug for an old hypothesis?
Topics: Adenosine; Animals; Blood Coagulation; Blood Platelets; Carotid Artery Injuries; Carotid Artery, Common; Carotid Stenosis; Cell Proliferation; Coronary Restenosis; Fibrinolytic Agents; Humans; Mice; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Tunica Intima | 2010 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Approval; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States | 2011 |
Fresh from the pipeline. Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2011 |
The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines.
Topics: Adenosine; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Thienopyridines; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
Topics: Adenosine; Adenosine Monophosphate; Animals; Disease Models, Animal; Drug Synergism; Enzyme Inhibitors; Fibrinolytic Agents; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphoric Diester Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis | 2011 |
Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Cytoprotection; Platelet Activation; Protein Binding; Purinergic P2Y Receptor Antagonists; Rats; Rats, Inbred WKY; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
Stress cardiovascular MR in routine clinical practice: referral patterns, accuracy, tolerance, safety and incidental findings.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Bundle-Branch Block; Cardiomyopathies; Cardiotonic Agents; Chest Pain; Chronic Disease; Contrast Media; Coronary Stenosis; Cysts; Dobutamine; Exercise Test; Gadolinium DTPA; Heart Neoplasms; Heart Valve Diseases; Humans; Incidental Findings; Lipoma; Liver Diseases; Magnetic Resonance Angiography; Middle Aged; Multiple Pulmonary Nodules; Referral and Consultation; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Thrombosis; Vasodilator Agents; Ventricular Dysfunction, Left | 2012 |
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Antiplatelet therapy - ticagrelor.
Topics: Adenosine; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Treatment Outcome | 2012 |
BF066, a novel dual target antiplatelet agent without significant bleeding.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenine; Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Arachidonic Acid; Arterioles; Chlorides; Collagen; Ferric Compounds; Fibrinogen; Hemorrhage; Humans; Immobilized Proteins; Mice; Mice, Inbred C57BL; Oligopeptides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, Adenosine A2A; Thrombin; Thrombosis | 2012 |
What's new in the UA/NSTEMI guidelines?
Topics: Adenosine; Angina, Unstable; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Thrombosis; Ticagrelor | 2012 |
A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
Topics: Adenosine; Animals; Blood Coagulation Tests; Dose-Response Relationship, Drug; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Risk; Thiophenes; Thrombosis; Ticagrelor | 2013 |
INHIBITION BY ADENOSINE AND BY 2-CHLOROADENOSINE OF THE FORMATION AND EMBOLIZATION OF PLATELET THROMBI.
Topics: 2-Chloroadenosine; Adenosine; Blood Platelets; Nucleosides; Pharmacology; Rabbits; Research; Thrombosis; Wounds and Injuries | 1964 |
EFFECT OF ADENOSINE ON PLATELET ADHESIVENESS IN FASTING AND LIPAEMIC BLOODS.
Topics: Adenosine; Blood Platelets; Dietary Fats; Fasting; Humans; Lipids; Nucleosides; Pharmacology; Platelet Adhesiveness; Thrombosis | 1965 |
Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation.
Topics: Adenosine; Adenosine Monophosphate; Adenosine Triphosphatases; Animals; Antigens, CD; Apyrase; Blood Platelets; Bone Marrow Transplantation; Gene Expression; Humans; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Phenotype; Thrombosis; Transplantation Immunology | 2004 |
Treatment of saphenous vein graft thrombosis with distal protection, thrombectomy, and adenosine prior to reperfusion: a complete approach to preserving microvascular integrity.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Female; Graft Occlusion, Vascular; Humans; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Saphenous Vein; Stents; Thrombectomy; Thrombosis; Vasodilator Agents | 2004 |
Dual lumen catheters: more than just aspiration.
Topics: Adenosine; Biopsy, Fine-Needle; Cardiac Catheterization; Coronary Vessels; Embolism; Humans; Nitroprusside; Stents; Thrombosis; Vasodilation | 2006 |
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
Topics: Adenosine; Adenosine Triphosphate; Administration, Oral; Animals; Humans; Membrane Proteins; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor | 2007 |
Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury.
Topics: Adenosine; Alkynes; Animals; Antihypertensive Agents; Femoral Artery; Male; Purinergic P1 Receptor Agonists; Rats; Rats, Wistar; Thrombosis; Time Factors | 1995 |
Pancreas transplant functional salvage after segmental vascular thrombosis.
Topics: Adenosine; Adult; Allopurinol; Amylases; Blood Glucose; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Duodenum; Glutathione; Histocompatibility Testing; Humans; Insulin; Kidney Failure, Chronic; Kidney Transplantation; Male; Organ Preservation; Organ Preservation Solutions; Pancreas Transplantation; Raffinose; Solutions; Spleen; Thrombosis; Tomography, X-Ray Computed; Transplantation, Homologous | 1993 |
Incidence of vascular complications in kidney transplantation: is there any interference with the nature of the perfusion solution?
Topics: Adenosine; Adult; Allopurinol; Glutathione; Humans; Hypertonic Solutions; Insulin; Kidney Transplantation; Organ Preservation; Organ Preservation Solutions; Raffinose; Renal Artery Obstruction; Renal Veins; Thrombosis | 1994 |
Back-table renal allograft angioscopy and thrombolysis.
Topics: Adenosine; Allopurinol; Angioscopy; Glutathione; Humans; Insulin; Kidney Transplantation; Male; Middle Aged; Organ Preservation Solutions; Raffinose; Renal Artery Obstruction; Streptokinase; Thrombolytic Therapy; Thrombosis; Transplantation, Homologous | 1994 |
Prolonged preservation in University of Wisconsin solution associated with hepatic artery thrombosis after orthotopic liver transplantation.
Topics: Adenosine; Adult; Aged; Allopurinol; Child, Preschool; Cold Temperature; Glutathione; Hepatic Artery; Humans; Insulin; Ischemia; Liver; Liver Transplantation; Middle Aged; Organ Preservation; Organ Preservation Solutions; Raffinose; Thrombosis; Time Factors; Ultrasonography | 1993 |
Donor criteria and technical aspects of procurement in combined pancreas and kidney transplantation from non-heart-beating cadavers.
Topics: Adenosine; Adolescent; Adult; Allopurinol; Cadaver; Female; Glutathione; Graft Rejection; Humans; Insulin; Ischemia; Isotonic Solutions; Kidney; Kidney Transplantation; Male; Middle Aged; Organ Preservation; Organ Preservation Solutions; Pancreas; Pancreas Transplantation; Perfusion; Raffinose; Ringer's Solution; Therapeutic Irrigation; Thrombosis; Tissue and Organ Procurement; Tissue Donors | 1995 |
Preserved vascular homograft for revascularization of pediatric liver transplant: a clinical, histological, and bacteriological study.
Topics: Adenosine; Adolescent; Allopurinol; Bacteria; Child; Child, Preschool; Cryopreservation; Endothelium, Vascular; Glutathione; Humans; Iliac Artery; Iliac Vein; Infant; Insulin; Isotonic Solutions; Liver; Liver Transplantation; Organ Preservation Solutions; Postoperative Complications; Raffinose; Retrospective Studies; Thrombosis; Tissue Donors; Vascular Patency | 1999 |
Experimental rupture of atherosclerotic lesions increases distal vascular resistance: a limiting factor to the success of infarct angioplasty.
Topics: Adenosine; Animals; Arteriosclerosis; Capillary Permeability; Hindlimb; Iliac Artery; Microcirculation; Models, Animal; Muscle, Skeletal; Nitroglycerin; Nitroprusside; Rabbits; Regional Blood Flow; Rupture, Spontaneous; Thrombosis; Vascular Resistance; Vasodilation | 2002 |
A membrane-bound enzyme in rabbit aorta capable of inhibiting adenosine-diphosphate-induced platelet aggregation.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Aorta; Apyrase; Cell Extracts; Cell Membrane; Phosphoric Monoester Hydrolases; Platelet Aggregation; Rabbits; Thrombosis | 1977 |
Regional administration of drugs to control thrombosis in artificial organs.
Topics: Adenosine; Animals; Artificial Organs; Blood Cell Count; Blood Coagulation; Blood Platelets; Dipyridamole; Drug Synergism; Kidneys, Artificial; Sheep; Thrombosis | 1976 |
Diffuse biliary tract injury after orthotopic liver transplantation.
Topics: Adenosine; Adolescent; Adult; Aged; Alanine Transaminase; Allopurinol; Aspartate Aminotransferases; Bile Duct Diseases; Biliary Tract Diseases; Child; Child, Preschool; Cholangitis; Follow-Up Studies; Glutathione; Graft Survival; Hepatic Artery; Humans; Hypertonic Solutions; Infant; Infant, Newborn; Insulin; Jaundice; Liver; Liver Transplantation; Middle Aged; Organ Preservation; Organ Preservation Solutions; Raffinose; Reoperation; Retrospective Studies; Solutions; Thrombosis | 1992 |
Improved arterial allograft preservation with the University of Wisconsin solution.
Topics: Adenosine; Allopurinol; Animals; Dogs; Female; Glutathione; Iliac Artery; Insulin; Microscopy, Electron; Muscle, Smooth, Vascular; Organ Preservation; Organ Preservation Solutions; Raffinose; Solutions; Thrombosis; Transplantation, Homologous | 1991 |
Current status of organ preservation with University of Wisconsin solution.
Topics: Adenosine; Adolescent; Allopurinol; Child; Child, Preschool; Glutathione; Graft Survival; Hepatic Artery; Humans; Infant; Insulin; Kidney Transplantation; Liver; Liver Transplantation; Organ Preservation; Organ Preservation Solutions; Pancreas; Pancreas Transplantation; Postoperative Complications; Raffinose; Reoperation; Solutions; Thrombosis; Time Factors | 1991 |
Red blood cells mediate spontaneous aggregation of platelets in whole blood.
Topics: 2-Chloroadenosine; Adenosine; Adult; Aged; Aspirin; Epoprostenol; Erythrocytes; Humans; Iloprost; In Vitro Techniques; Middle Aged; Platelet Aggregation; Platelet Count; Sulfonamides; Thrombosis | 1987 |
Leucocytes and thrombosis. 3. Effect on white cell behaviour of substances which induce or inhibit platelet aggregation.
Topics: Adenosine; Aspirin; Catecholamines; Collagen; Dipyridamole; Epinephrine; Isoproterenol; Leukocytes; Norepinephrine; Serotonin; Tendons; Thrombosis | 1973 |
Inhibition of platelet-induced thrombus formation.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Diseases; Dipyridamole; Epinephrine; Glomerulonephritis; Heart Valve Prosthesis; Humans; Hypertension, Malignant; Ischemia; Myocardial Infarction; Platelet Adhesiveness; Postoperative Complications; Prostaglandins; Pyrimidines; Thromboembolism; Thrombophlebitis; Thrombosis; Xanthines | 1974 |
Involvement of platelets and microthrombi in experimental decompression sickness: similarities with disseminated intravascular coagulation.
Topics: Adenosine; Adenosine Diphosphate; Air; Animals; Blood Cell Count; Blood Platelets; Cerebral Cortex; Decompression Sickness; Disseminated Intravascular Coagulation; Erythrocyte Aggregation; Injections, Intra-Arterial; Injections, Intravenous; Lung; Male; Platelet Adhesiveness; Rabbits; Rats; Serotonin; Thrombosis | 1971 |